Patient and Consumer reps needed for mental health – ALIGNED – study
Who: The George Institute – ALIGNED Study- Steering Committee
Application deadline: Thursday, 31 December 2020
The ALIGNED study
Major Depressive Disorder (MDD) is a serious and debilitating condition currently affecting approximately 10-15% of Australians (up to 3 million). MDD is treated mainly with antidepressant medications. Current antidepressant therapy follows one-size-fits-all dosing and a trial-and-error approach, which reduces the success of treatment.
The ALIGNED study investigates how pharmacogenomics and biomarkers such as neuroimaging can be used to provide more tailored treatment. Pharmacogenomics is the study of how genetic variations affect an individual’s likely response to therapeutic medications. Pharmacogenomics-guided therapy has the potential to offer a more effective precision approach to treatment selection.
Despite increasing evidence, the clinical uptake of mental health Pharmacogenomics in Australia has been limited. This study aims to address the current gaps in evidence and to combine new and emerging technology.
One of the goals of this project is to lobby for Medicare rebate for PG testing to guide treatment for major depressive disorder.
The ALIGNED study is funded by the ‘Medical Research Future Fund’ and is lead by a team of clinicians/academics who are experts in their respective fields. The study will recruit participants in New South Wales, Victoria and Western Australia.
The George Institute for Global Health is responsible for overseeing overall conduct and project management of the study.
Consumers for Steering Committee
Steering Committee membership includes healthcare providers (including experts in mental health), statisticians, health economists, epidemiologists with clinical and/or research expertise relevant to the design and conduct of ALIGNED and patient and consumer representatives.
The Steering committee is expected to meet every 4 to 6 weeks during start-up, then 2-monthly during initial recruitment, and then quarterly each year. It is expected that not all members will be able to attend all meetings. All meetings will be conducted via videoconference.
Patient and consumer representatives will be invited to provide feedback on study processes, protocol, participant information sheet and consent forms, data collection procedures and study assessment schedules, in their capacity as a person with lived experience.
The first meeting will take place in mid-November 2020 and The George Institute will pay members a sitting fee of up to $200 per meeting, depending on the requirements such as need to review documents.
To find out more and apply for membership, please contact Niru Wijesuriya, Senior Clinical Research Associate at the George Institute on 02 8052 4490 or via email at firstname.lastname@example.org